In vivo 123I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients

Rationale: Single photon emission computed tomography (SPECT) using 123I iodobenzamide (IBZM) as tracer substance has been shown to be a useful tool to visualize dopamine 2 (D2) receptor occupancy. Objectives: We investigated the striatal D2 receptor occupancy of zotepine which is referred to the cl...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacologia 2001-09, Vol.157 (3), p.236-242
Main Authors: BARNAS, Christian, QUINER, Sylvia, TAUSCHER, Johannes, HILGER, Eva, WILLEIT, Matthäus, KÜFFERLE, Bernd, ASENBAUM, Susanne, BRÜCKE, Thomas, RAO, Marie-Luise, KASPER, Siegfried
Format: Article
Language:English
Subjects:
Antipsychotics
Biological and medical sciences
Computed tomography
Dopamine
Dopamine D2 receptors
Extrapyramidal system
Medical sciences
Neostriatum
Neuropharmacology
Patients
Pharmacology. Drug treatments
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Single photon emission computed tomography
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale: Single photon emission computed tomography (SPECT) using 123I iodobenzamide (IBZM) as tracer substance has been shown to be a useful tool to visualize dopamine 2 (D2) receptor occupancy. Objectives: We investigated the striatal D2 receptor occupancy of zotepine which is referred to the class of atypical antipsychotic drugs. Methods:123I IBZM and SPECT were used to visualize striatal dopamine 2 (D2) receptor occupancy in zotepine-treated schizophrenic patients. Two groups of schizophrenic patients receiving either 150 mg/day zotepine (n=6) or 300 mg/day (n=6) underwent examination. For the quantification of striatal D2 receptor occupancy, striatal IBZM binding in patients treated with antipsychotics was compared to untreated healthy controls (n=8) reported earlier. Results: Zotepine led to a mean overall striatal D2 receptor occupancy of 73%. Patients with 150 mg daily showed a significantly lower occupancy (65.8%, SD=6.2) than patients with 300 mg/day (77.8%, SD=10.7; P
ISSN:0033-3158
1432-2072
DOI:10.1007/s002130100813